PharmNovo PN6047

Innovation in pain relief

PharmNovo PN6047, a novel delta opioid biased receptor agonist for safe and effective treatment of chronic pain.

Chronic pain currently affects over 100 million people in Europe and nearly 30% of the world’s population.

It has a highly detrimental effect on sufferers’ quality of life, impairing everyday activities and significantly limiting normal social functioning. Chronic pain is frequently associated with poor mental health exacerbating the burden on both sufferers and their families. The condition imposes personal financial hardship due to the inability to work or regular absenteeism and it has a severe impact on European economies costing EU nations up to 3% (441b ₏) of their GDP in healthcare and social costs. Unfortunately, the available chronic pain medicines are only partially effective and are associated with potentially fatal physical side effects and abuse potential resulting, notably, in the opioid epidemic in the USA. New treatments are desperately needed.

Big Pharma has missed a significant opportunity in failing to capitalize on the very impressive pre-clinical properties of delta opioid receptor agonists (DORA)s, a class of compounds that shows great efficacy in animal models of chronic pain without significant side effects. Companies abandoned DORA development since early compounds produced seizures, but PharmNovo has developed a novel highly selective DORA PN6047, which is potent and effective in neuropathic pain models and has no

Our lead candidate PN 6047 is selective and potent in animal chronic pain tests and has none of the unwanted side effects of existing pain medicines.

seizure-causing properties. The compound has been designed to couple delta receptors to G protein signalling pathways in a biased fashion, thereby optimising its pharmacological profile. It is thus designated as a DOBRA (delta opioid biased receptor agonist).

PN6047 is potent and very selective, having no significant affinity for any other receptors, ion channels or enzymes tested, in reducing pain in sciatic nerveligated (SNL) rats, a validated model of allodynia (normal innocuous stimuli perceived as painful). It acts peripherally against chronic pain, but it also has antidepressant-like and antitussive activity. There is no analgesic tolerance after prolonged treatment with PN6047 and no indications of toxicity or unwanted side effects in pre-clinical studies.

PharmNovo’s initial clinical targets are the hyperalgesia and allodynia frequently suffered in neuropathic pain states such as post-herpetic neuralgia and painful diabetic neuropathy, although additional therapeutic indications are credible.

PharmNovo has successfully completed preclinical studies with PN6047 demonstrating its potential to be a first in class medicine for neuropathic pain treatment with significant advantages over existing medicines and our solution is likely to disrupt the chronic pain therapeutics market. According to our market analysis, the current total target market for our candidate compound is close to 60b $ and even a relatively small share in this via sales of PN6047 would generate very impressive revenues for PharmNovo.

Our mission is to create a medicine for better treatment of patients with chronic pain.

Our next step is to complete large-scale production of PN6047 and to undertake GLP Regulatory Toxicology testing, the next crucial de-risking step in the drug development process. We will then prepare for human safety and proof of concept trials. PharmNovo’s business strategy is to out-license PN6047 to a chosen Pharma partner with the infrastructure required for registration and market launch. Given the long experience of our team in taking drugs to the market, PharmNovo is ideally positioned to exploit the favourable market conditions and to establish PN6047 as the first line prescription medicine for neuropathic pain treatment.

PharmNovo now seeks investments to fund large-scale production of PN6047, regulatory toxicology and first in man trials.

Please see pharmnovo.com for disclaimer.

Innovation in pain relief

PharmNovo AB Registered in Sweden. Company number 556739-7368.

Registered office address: c/o Medicon Village, Scheeletorget 1, SE-223 81 Lund, Sweden. pharmnovo.com